VILAS Ventures supports CND Life Sciences’ $13.5M Series A3 to expand Syn-One Test® for Parkinson’s and advance neurodegenerative diagnostics.

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

The clinical, cardiovascular and neuroendocrine profile of ampreloxetine showed target engagement of residual peripheral autonomic neurons and a sustained standing blood pressure effect, which is ...

Get Instant Summarized Text (Gist) Recent advances in PET tracers enable in vivo visualization of α-synuclein aggregates, a hallmark of synucleinopathies such as Parkinson’s disease, multiple ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease (PD), ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

Background: Exercise is increasingly recognized as a beneficial intervention for Parkinson’s disease (PD), yet the optimal type and intensity of exercise remain unclear. This study investigated the ...

Objective: Characteristic ocular symptoms are expected to serve as potential biomarkers for early diagnosis of Parkinson’s disease (PD). However, possible ocular impairments in PD patients are rarely ...